Immune defects in breast cancer patients after radiotherapy

Leanna J. Standish, Carolyn Torkelson, Frank A. Hamill, Daesong Yim, Alicia Hill-Force, Annette Fitzpatrick, Monica Olsen, Sandi Schildt, Erin Sweet, Cynthia A. Wenner, Mark R. Martzen

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


The purpose of this study was to evaluate the immune status of women with stage I-III breast cancer after receiving external beam radiotherapy (RT). Fourteen stage I-III, estrogen or progesterone receptor-positive or-negative (FER/PR +\-), postsurgical breast cancer patients undergoing a standard course of chemotherapy and radiation were studied. Complete blood counts (CBC) with differential, phagocytic activity, natural killer (NK) cell functional activity, and tumor necrosis factor-α (TNF-α) and interferon-γ cytokine activity were measured immediately before and for the six weeks following the completion of radiation therapy. Fatigue levels after completion of RT were measured using the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. Nonparametric statistical methods (Wilcoxon rank and Spearman correlations) were used to analyze the data. Compared with postchemotherapy, following the completion of RT, these breast cancer patients showed lymphopenia, low functional activity of natural killer lymphocytes, decreased monocyte phagocytic activity, and decreased TNF-α production but no neutropenia, no anemia, and no change in interferon-γ production. Lymphocyte count did not return to normal by the end of the 6-week post-RT observation period. The severity of lymphopenia and low natural killer cell activity was related to RT area but not radiation dose. Patients did not report significant fatigue levels for the 6 weeks after completing RT. Significant decreases in the numbers and functions of cells from both the innate and adaptive immune system were detected following a standard course of radiation therapy for the treatment of breast cancer. Immune deficits in lymphocyte populations and TNF-α production, should they persist, may have consequences for immune response to residual or recurrent malignancy following completion of conventional treatment. The use of adjunctive immune therapies which target these specific defects may be warranted in the post-treatment period.

Original languageEnglish (US)
Pages (from-to)110-121
Number of pages12
JournalJournal of the Society for Integrative Oncology
Issue number3
StatePublished - Jun 2008


  • Breast cancer
  • Fatigue
  • Immune defects
  • Natural killer cell activity
  • Phagocytic activity
  • Radiotherapy
  • Tumor necrosis factor


Dive into the research topics of 'Immune defects in breast cancer patients after radiotherapy'. Together they form a unique fingerprint.

Cite this